OHE Lunchtime Seminar: Economic Evaluation for Decision-Making and the Value of Access to Individual Patient Data
The international debate surrounding the opportunities offered by (and the challenges associated with) a more systematic approach to patient-level data sharing has yet to settle. The arguments in favour and against are well known, and the discussion so far has…
13/02/17 12:00 am
The international debate surrounding the opportunities offered by (and the challenges associated with) a more systematic approach to patient-level data sharing has yet to settle. The arguments in favour and against are well known, and the discussion so far has involved a wide range of stakeholders with potentially competing interests.
To successfully support healthcare decision-making, cost-effectiveness analysis (CEA) must consider and synthesise all (relevant) available evidence relating to the clinical effectiveness, health-related quality of life (HRQoL) and costs of the health technologies under scrutiny. The evidence base available to the HTA agency is often multifaceted and fragmented, comprising a mix of aggregate (or summary level data – AD) and individual patient-level data (IPD). This poses a series of methodological issues for those tasked with providing information to support policy making.
This lecture will offer a health economics perspective on the value of access to individual patient-level data (IPD) to guide HTA-like and other forms of decision-making in healthcare.
Professor Andrea Manca’s research focuses on developing methodological solutions to address the issues faced by policy makers when trying to analyse and interpret health economics and outcome research data. This involves the use of statistical and decision modelling techniques for the analysis of cost effectiveness data. He has 17 years experience in applied health economics research and policy and has evaluated a wide range of health technologies (therapeutic medical devices, drugs, diagnostics and non pharmaceutical interventions) in a number of different clinical areas. He received the 2008 ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research for his contributions to the analysis of multinational individual patient level cost effectiveness data literature. He is member of the NICE Technology Appraisal Committee, Deputy Chair of the UK National Institute of Health Research (NIHR) Doctoral Research Fellowships panel, and member of the ISPOR Bernie O’Brien New Investigator Award panel.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!